Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women

OE. Iversen, MJ. Miranda, A. Ulied, T. Soerdal, E. Lazarus, K. Chokephaibulkit, SL. Block, A. Skrivanek, AG. Nur Azurah, SM. Fong, V. Dvorak, KH. Kim, RM. Cestero, M. Berkovitch, M. Ceyhan, MC. Ellison, MA. Ritter, SS. Yuan, MJ. DiNubile, AJ....

. 2016 ; 316 (22) : 2411-2421.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013372
E-zdroje Online Plný text

NLK Open Access Digital Library od 1998-01-01 do Před 6 měsíci
Medline Complete (EBSCOhost) od 1998-01-07 do Před 1 měsícem

Odkazy

PubMed 27893068
DOI 10.1001/jama.2016.17615
Knihovny.cz E-zdroje

Importance: Human papillomavirus (HPV) infections cause anogenital cancers and warts. The 9-valent HPV vaccine provides protection against 7 high-risk types of HPV responsible for 90% of cervical cancers and 2 other HPV types accounting for 90% of genital warts. Objective: To determine whether HPV type-specific antibody responses would be noninferior among girls and boys aged 9 to 14 years after receiving 2 doses of the 9-valent HPV vaccine compared with adolescent girls and young women aged 16 to 26 years receiving 3 doses. Design, Setting, and Participants: Open-label, noninferiority, immunogenicity trial conducted at 52 ambulatory care sites in 15 countries. The study was initiated on December 16, 2013, with the last participant visit for this report on June 19, 2015. Five cohorts were enrolled: (1) girls aged 9 to 14 years to receive 2 doses 6 months apart (n = 301); (2) boys aged 9 to 14 years to receive 2 doses 6 months apart (n = 301); (3) girls and boys aged 9 to 14 years to receive 2 doses 12 months apart (n = 301); (4) girls aged 9 to 14 years to receive 3 doses over 6 months (n = 301); and (5) a control group of adolescent girls and young women aged 16 to 26 years to receive 3 doses over 6 months (n = 314). Interventions: Two doses of the 9-valent HPV vaccine administered 6 or 12 months apart or 3 doses administered over 6 months. Main Outcomes and Measures: The primary end point was prespecified as the antibody response against each HPV type assessed 1 month after the last dose using a competitive immunoassay. Each of the three 2-dose regimens was compared with the standard 3-dose schedule in adolescent girls and young women using a noninferiority margin of 0.67 for the ratio of the antibody geometric mean titers. Results: Of the 1518 participants (753 girls [mean age, 11.4 years]; 451 boys [mean age, 11.5 years]; and 314 adolescent girls and young women [mean age, 21.0 years]), 1474 completed the study and data from 1377 were analyzed. At 4 weeks after the last dose, HPV antibody responses in girls and boys given 2 doses were noninferior to HPV antibody responses in adolescent girls and young women given 3 doses (P < .001 for each HPV type). Compared with adolescent girls and young women who received 3 doses over 6 months, the 1-sided 97.5% CIs for the ratio of HPV antibody geometric mean titers at 1 month after the last dose across the 9 HPV subtypes ranged from 1.36 to ∞ to 2.50 to ∞ for girls who received 2 doses 6 months apart; from 1.37 to ∞ to 2.55 to ∞ for boys who received 2 doses 6 months apart; and from 1.61 to ∞ to 5.36 to ∞ for girls and boys who received 2 doses 12 months apart. Conclusions and Relevance: Among girls and boys aged 9 to 14 years receiving 2-dose regimens of a 9-valent HPV vaccine separated by 6 or 12 months, immunogenicity 4 weeks after the last dose was noninferior to a 3-dose regimen in a cohort of adolescent girls and young women. Further research is needed to assess persistence of antibody responses and effects on clinical outcomes. Trial Registration: clinicaltrials.gov Identifier: NCT01984697.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013372
003      
CZ-PrNML
005      
20170502101301.0
007      
ta
008      
170413s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1001/jama.2016.17615 $2 doi
035    __
$a (PubMed)27893068
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Iversen, Ole-Erik $u Department of Obstetrics and Gynecology, Haukeland University Hospital, University of Bergen, Bergen, Norway.
245    10
$a Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women / $c OE. Iversen, MJ. Miranda, A. Ulied, T. Soerdal, E. Lazarus, K. Chokephaibulkit, SL. Block, A. Skrivanek, AG. Nur Azurah, SM. Fong, V. Dvorak, KH. Kim, RM. Cestero, M. Berkovitch, M. Ceyhan, MC. Ellison, MA. Ritter, SS. Yuan, MJ. DiNubile, AJ. Saah, A. Luxembourg,
520    9_
$a Importance: Human papillomavirus (HPV) infections cause anogenital cancers and warts. The 9-valent HPV vaccine provides protection against 7 high-risk types of HPV responsible for 90% of cervical cancers and 2 other HPV types accounting for 90% of genital warts. Objective: To determine whether HPV type-specific antibody responses would be noninferior among girls and boys aged 9 to 14 years after receiving 2 doses of the 9-valent HPV vaccine compared with adolescent girls and young women aged 16 to 26 years receiving 3 doses. Design, Setting, and Participants: Open-label, noninferiority, immunogenicity trial conducted at 52 ambulatory care sites in 15 countries. The study was initiated on December 16, 2013, with the last participant visit for this report on June 19, 2015. Five cohorts were enrolled: (1) girls aged 9 to 14 years to receive 2 doses 6 months apart (n = 301); (2) boys aged 9 to 14 years to receive 2 doses 6 months apart (n = 301); (3) girls and boys aged 9 to 14 years to receive 2 doses 12 months apart (n = 301); (4) girls aged 9 to 14 years to receive 3 doses over 6 months (n = 301); and (5) a control group of adolescent girls and young women aged 16 to 26 years to receive 3 doses over 6 months (n = 314). Interventions: Two doses of the 9-valent HPV vaccine administered 6 or 12 months apart or 3 doses administered over 6 months. Main Outcomes and Measures: The primary end point was prespecified as the antibody response against each HPV type assessed 1 month after the last dose using a competitive immunoassay. Each of the three 2-dose regimens was compared with the standard 3-dose schedule in adolescent girls and young women using a noninferiority margin of 0.67 for the ratio of the antibody geometric mean titers. Results: Of the 1518 participants (753 girls [mean age, 11.4 years]; 451 boys [mean age, 11.5 years]; and 314 adolescent girls and young women [mean age, 21.0 years]), 1474 completed the study and data from 1377 were analyzed. At 4 weeks after the last dose, HPV antibody responses in girls and boys given 2 doses were noninferior to HPV antibody responses in adolescent girls and young women given 3 doses (P < .001 for each HPV type). Compared with adolescent girls and young women who received 3 doses over 6 months, the 1-sided 97.5% CIs for the ratio of HPV antibody geometric mean titers at 1 month after the last dose across the 9 HPV subtypes ranged from 1.36 to ∞ to 2.50 to ∞ for girls who received 2 doses 6 months apart; from 1.37 to ∞ to 2.55 to ∞ for boys who received 2 doses 6 months apart; and from 1.61 to ∞ to 5.36 to ∞ for girls and boys who received 2 doses 12 months apart. Conclusions and Relevance: Among girls and boys aged 9 to 14 years receiving 2-dose regimens of a 9-valent HPV vaccine separated by 6 or 12 months, immunogenicity 4 weeks after the last dose was noninferior to a 3-dose regimen in a cohort of adolescent girls and young women. Further research is needed to assess persistence of antibody responses and effects on clinical outcomes. Trial Registration: clinicaltrials.gov Identifier: NCT01984697.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a specificita protilátek $7 D000918
650    _2
$a dítě $7 D002648
650    _2
$a kohortové studie $7 D015331
650    _2
$a fyziologie výživy seniorů $7 D058620
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    12
$a očkovací schéma $7 D007115
650    _2
$a imunogenicita vakcíny $7 D000071497
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a Papillomaviridae $x genetika $x imunologie $7 D027383
650    _2
$a infekce papilomavirem $x prevence a kontrola $7 D030361
650    _2
$a vakcíny proti papilomavirům $x aplikace a dávkování $x škodlivé účinky $x imunologie $7 D053918
650    _2
$a sexuální faktory $7 D012737
650    _2
$a časové faktory $7 D013997
650    _2
$a mladý dospělý $7 D055815
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Miranda, Maria Jose $u Instituto Chileno de Medicina Reproductiva, Santiago, Chile.
700    1_
$a Ulied, Angels $u Centre d'Atèncio Primària, EBA Centelles, Barcelona, Spain.
700    1_
$a Soerdal, Terje $u Medicus, Clinical Trials, Trondheim, Norway.
700    1_
$a Lazarus, Erica $u Perinatal HIV Research Unit, Baragwanath Hospital, Johannesburg, South Africa.
700    1_
$a Chokephaibulkit, Kulkanya $u Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
700    1_
$a Block, Stan L $u Kentucky Pediatric and Adult Research, Bardstown.
700    1_
$a Skrivanek, Ales $u G-CENTRUM Olomouc, Olomouc, Czech Republic.
700    1_
$a Nur Azurah, Abdul Ghani $u Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
700    1_
$a Fong, Siew Moy $u Sabah Woman's and Children's Hospital, Hospital Likas, Sabah, Malaysia.
700    1_
$a Dvorak, Vladimir $u Centrum Ambulantní, Brno, Czech Republic.
700    1_
$a Kim, Kyung-Hyo $u Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Republic of Korea.
700    1_
$a Cestero, Ramon M $u Women's Research Center of Redlands, Terracina Medical Center, Redlands, California.
700    1_
$a Berkovitch, Matitiahu $u Assaf-Harofeh Medical Center, Zerifin, Israel.
700    1_
$a Ceyhan, Mehmet $u Hacettepe Üniversitesi Beytepe Kampüsü, Ankara, Turkey.
700    1_
$a Ellison, Misoo C $u Merck & Co Inc, Kenilworth, New Jersey.
700    1_
$a Ritter, Michael A $u Merck & Co Inc, Kenilworth, New Jersey.
700    1_
$a Yuan, Shuai S $u Merck & Co Inc, Kenilworth, New Jersey.
700    1_
$a DiNubile, Mark J $u Merck & Co Inc, Kenilworth, New Jersey.
700    1_
$a Saah, Alfred J $u Merck & Co Inc, Kenilworth, New Jersey.
700    1_
$a Luxembourg, Alain $u Merck & Co Inc, Kenilworth, New Jersey.
773    0_
$w MED00002973 $t JAMA $x 1538-3598 $g Roč. 316, č. 22 (2016), s. 2411-2421
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27893068 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170502101627 $b ABA008
999    __
$a ok $b bmc $g 1199837 $s 974150
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 316 $c 22 $d 2411-2421 $i 1538-3598 $m JAMA (Chicago, Ill.) $n JAMA $x MED00002973
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace